Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Culp Inc
CULP
$43.8M
| $19.9M | 0.03% |
612,900
-5,400
| -0.9% | -$174K |
|
852
American Public Education
APEI
$826M
| $19.9M | 0.03% |
841,600
+25,700
| +3% | +$588K |
|
853
Quanex
NX
$1B
| $19.9M | 0.03% |
940,500
-175,302
| -16% | -$3.56M |
|
854
PENN Entertainment
PENN
$2.57B
| $19.9M | 0.03% |
929,500
+737,800
| +385% | +$14.5M |
|
855
Park Aerospace
PKE
$828M
| $19.8M | 0.03% |
1,073,000
+25,500
| +2% | +$443K |
|
|
BSTC
856
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $19.7M | 0.03% |
398,800
+46,173
| +13% | +$2.42M |
|
|
PARAA
857
DELISTED
Paramount Global Class A
PARAA
| $19.7M | 0.03% |
304,400
+4,900
| +2% | +$320K |
|
|
INST
858
DELISTED
Instructure, Inc.
INST
| $19.6M | 0.03% |
664,590
+557,255
| +519% | +$14.2M |
|
859
Masco
MAS
$14.7B
| $19.6M | 0.03% |
513,000
-40,600
| -7% | -$1.49M |
|
860
First American
FAF
$7.38B
| $19.6M | 0.03% |
438,500
-80,000
| -15% | -$3.38M |
|
861
Bio-Rad Laboratories Class A
BIO
$9.68B
| $19.6M | 0.03% |
86,500
-3,500
| -4% | -$763K |
|
|
TRUE
862
DELISTED
TrueCar
TRUE
| $19.5M | 0.02% |
978,900
+754,500
| +336% | +$13M |
|
863
Enviri
NVRI
$583M
| $19.5M | 0.02% |
1,208,400
-333,900
| -22% | -$4.81M |
|
|
WRK
864
DELISTED
WestRock Company
WRK
| $19.4M | 0.02% |
+343,062
| New | +$18.6M |
|
|
NXRT
865
NexPoint Residential Trust
NXRT
$631M
| $19.4M | 0.02% |
780,100
+129,000
| +20% | +$3.22M |
|
|
DEA
866
Easterly Government Properties
DEA
$1.16B
| $19.4M | 0.02% |
370,672
+277,750
| +299% | +$14.2M |
|
867
Crocs
CROX
$6.26B
| $19.4M | 0.02% |
2,515,710
+388,074
| +18% | +$2.6M |
|
|
HTO
868
H2O America
HTO
$2.62B
| $19.4M | 0.02% |
393,600
+26,600
| +7% | +$1.32M |
|
869
Winmark
WINA
$1.26B
| $19.4M | 0.02% |
150,101
+15,801
| +12% | +$2M |
|
870
Sterling Infrastructure
STRL
$16.8B
| $19.3M | 0.02% |
1,479,900
+370,800
| +33% | +$3.78M |
|
|
DHC
871
Diversified Healthcare Trust
DHC
$2.02B
| $19.3M | 0.02% |
944,500
+198,100
| +27% | +$4.23M |
|
872
Bassett Furniture
BSET
$171M
| $19.2M | 0.02% |
506,300
+5,100
| +1% | +$153K |
|
873
FNB Corp
FNB
$6.86B
| $19.2M | 0.02% |
1,355,100
-657,128
| -33% | -$9.25M |
|
874
TriCo Bancshares
TCBK
$1.84B
| $19.2M | 0.02% |
545,792
-27,245
| -5% | -$960K |
|
|
TWO
875
Two Harbors Investment
TWO
$1.27B
| $19.2M | 0.02% |
241,950
+105,400
| +77% | +$8.43M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.